Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Gymnemic Acids Stabilize the Yeast Form of Candida albicans and Enhance Action of Antifungal Drugs

By BiotechDaily International staff writers
Posted on 24 Sep 2013
Image: Leaves of the medicinal plant Gymnema sylvestre (Photo courtesy of Wikimedia Commons).
Image: Leaves of the medicinal plant Gymnema sylvestre (Photo courtesy of Wikimedia Commons).
Image: Gymnemic acids prevent C. albicans yeast-to-hyphal transition and hyphal growths. Scale bars: five micrometers (Photo courtesy of Kansas State University).
Image: Gymnemic acids prevent C. albicans yeast-to-hyphal transition and hyphal growths. Scale bars: five micrometers (Photo courtesy of Kansas State University).
Small molecules isolated and purified from leaves of the ancient medicinal plant Gymnema sylvestre inhibit yeast-to-hypha conversion and hyphal growth in the fungus Candida albicans, which greatly enhances the effect of antifungal drug treatments.

Candida albicans is a diploid fungus that grows both as yeast and filamentous cells and is a causal agent of opportunistic oral and genital infections in humans. Systemic fungal infections, including those by C. albicans, have emerged as important causes of morbidity and mortality in immunocompromised patients. Furthermore, C. albicans biofilms may form on the surface of implantable medical devices, while hospital-acquired infections by C. albicans have become a cause of major health concerns.

Investigators at Kansas State University (Manhattan, USA) isolated and purified gymnemic acids (GAs) from Gymnema sylvestre. They reported in the September 11, 2013, online edition of the journal PLOS ONE that purified GAs had no effect on the growth and viability of C. albicans yeast cells but inhibited its yeast-to-hypha conversion under several hypha-inducing conditions, including the presence of serum. Moreover, GAs promoted the conversion of C. albicans hyphae into yeast cells under hypha inducing conditions. In a model system, GAs inhibited the formation of invasive hyphae from C. albicans-infected Caenorhabditis elegans worms and rescued the worms from being killed by the fungus.

In addition to their effects on C. albicans, GAs also inhibited conidial germination and hyphal growth of another fungus, Aspergillus.

"We have shown that this compound is safe to use because it does not hurt our body cells, yet it blocks the virulence of this fungus under in vitro conditions," said senior author Dr. Govindsamy Vediyappan, assistant professor of biology at Kansas State University. "Taking the medicine could potentially help patients control the invasive growth of the fungus."

C. albicans also makes a biofilm that can be difficult to treat. The investigators found that the gymnemic acid compounds converted the biofilm back to treatable yeast cells.

"This compound prevents the biofilm formation because hyphae are the major builders of biofilms and biofilms are resistant to antifungals," said Dr. Vediyappan. "Yeast cells by themselves cannot make biofilms and are sensitive to antifungal treatments."

Related Links:
Kansas State University


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.